Export 13 results:
Author Title [ Type(Desc)] Year
Filters: Author is Belshe, R  [Clear All Filters]
Journal Article
R. W. Frenck, Jr, Belshe, R., Brady, R. C., Winokur, P. L., Campbell, J. D., Treanor, J., Hay, C. M., Dekker, C. L., Walter, Jr., E. B., TR, C., KM, E., Hill, H., Wolff, M., Leduc, T., and Tornieporth, N., Comparison of the Immunogenicity and Safety of a Split-Virion, Inactivated, Trivalent Influenza Vaccine (Fluzone®) Administered by Intradermal and Intramuscular Route in Healthy Adults, Vaccine, vol. 29, pp. 5666-5674, 2011.
J. E. Ledgerwood, Bellamy, A. R., Belshe, R., Bernstein, D. I., Edupuganti, S., Patel, S. M., Renehan, P., Zajdowicz, T., Schwartz, R., Koup, R., Bailer, R. T., Yamshchikov, G. V., Enama, M. E., Sarwar, U., Larkin, B., Graham, B. S., and Team, andThe V. R. C. 70, DNA Priming for Seasonal Influenza Vaccine: a Phase 1b Double-Blind Randomized Clinical Trial, PLoS One, vol. 10, p. e0125914, 2015.
M. Laassri, Lottenbach, K., Belshe, R., Wolff, M., Rennels, M., Plotkin, S., and Chumakov, K., Effect of Different Vaccination Schedules on Excretion of Oral Poliovirus Vaccine Strains, J Infect Dis, vol. 192, pp. 2092-2098, 2005.
D. I. Bernstein, Edwards, K. M., Dekker, C. L., Belshe, R., Talbot, H. K., Graham, I. L., Noah, D. L., He, F., and Hill, H., Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in Adults, J Infec Dis, vol. 197, pp. 667-675, 2008.
J. Treanor, Keitel, W., Belshe, R., Campbell, J., Schiff, G., Zangwill, K., Wolff, M., Klimov, A., Levandowski, R., and Lambert, L., Evaluation of a Single Dose of Half Strength Inactivated Influenza Vaccine in Healthy Adults, Vaccine, vol. 20, pp. 1099-1105, 2002.
M. L. Clements-Mann, Weinhold, K., Matthews, T. J., Graham, B. S., Gorse, G. J., Keefer, M. C., McElrath, M. J., Hsieh, R. H., Mestecky, J., Zolla-Pazner, S., Mascola, J., Schwartz, D., Siliciano, R., Corey, L., Wright, P. F., Belshe, R., Dolin, R., Jackson, S., Xu, S., Fast, P., and Walker, M., Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults, J Infec Dis, vol. 177, pp. 1230-46, 1998.
M. L. Clements-Mann, Weinhold, K., Matthews, T. J., Graham, B. S., Gorse, G. J., Keefer, M. C., McElrath, M. J., Hsieh, R. H., Mestecky, J., Zolla-Pazner, S., Mascola, J., Schwartz, D., Siliciano, R., Corey, L., Wright, P. F., Belshe, R., Dolin, R., Jackson, S., Xu, S., Fast, P., Walker, M. C., Stablein, D., Excler, J. L., Tartaglia, J., and Paoletti, E., Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group., J Infect Dis, vol. 177, no. 5, pp. 1230-46, 1998.
M. J. McElrath, Corey, L., Montefiori, D., Wolff, M., Schwartz, D., Keefer, M., Belshe, R., Graham, B. S., Matthews, T., Wright, P., Gorse, G., Dolin, R., Berman, P., Francis, D., Duliege, A. M., Bolognesi, D., Stablein, D., Ketter, N., and Fast, P., A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group., AIDS Res Hum Retroviruses, vol. 16, no. 9, pp. 907-19, 2000.
M. J. McElrath, Corey, L., Montefiori, D., Wolff, M., Schwartz, D., Keefer, M., Belshe, R., Graham, B. S., Matthews, T., Wright, P., Gorse, G., Dolin, R., Berman, P., Francis, D., Duliege, A. M., Bolognesi, D., Stablein, D., Ketter, N., Fast, P., and Grou, theA. I. D. S. Vacci, A Phase II study of two HIV-1 envelope vaccines comparing their immunogenicity in populations at risk for acquiring HIV-1 infection, AIDS Res HumRetroviruses, vol. 16, pp. 907-19, 2000.
P. L. Winokur, Patel, S. M., Brady, R., Chen, W. H., El-Kamary, S. S., Edwards, K., Creech, C. B., Frey, S., Keitel, W. A., Belshe, R., Walter, E., Bellamy, A., Hill, H., and Group, T. V. T. E. U. - H. 3Nv, Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine, J Infect Dis, vol. 212, pp. 525-530, 2015.
R. C. Brady, Treanor, J. J., Atmar, R. L., Keitel, W. A., Edelman, R., Chen, W. H., Winokur, P., Belshe, R., Graham, I. L., Noah, D. L., Guo, K., and Hill, H., Safety and Immunogenicity of a Subvirion Inactivated Influenza a/H5N1 Vaccine With or Without Aluminum Hydroxide Among Healthy Elderly Adults, Vaccine, vol. 27, pp. 5091-5095, 2009.
S. Frey, Houghton, M., Coates, S., Abrignani, S., Chien, D., Rosa, D., Pileri, P., Ray, R., Di Bisceglie, A., Rinella, P., Hill, H., Wolff, M., Schultze, V., Han, J., Scharschmidt, B., and Belshe, R., Safety and Immunogenicity of HCV E1E2 Vaccine Adjuvanted with MF59 Administered to Healthy Adults, Vaccine, vol. 28, pp. 6367-6373, 2010.